Alpha Cognition Inc. (NASDAQ: ACOG) has reported promising progress in the commercialization of ZUNVEYL®, its treatment for Alzheimer's disease, during the second quarter of 2025. The drug has seen meaningful early adoption in the U.S. long-term care (LTC) market and achieved a significant regulatory milestone in China. By the end of the quarter, ZUNVEYL had been ordered in over 300 LTC facilities across priority regions, with 65% of these facilities placing repeat orders, indicating strong clinical confidence and operational fit.
The sales team's engagement with more than 3,700 healthcare professionals has resulted in both new and repeat prescriptions, with clinicians praising ZUNVEYL's cognitive and behavioral benefits alongside its favorable tolerability profile. A key development was the securing of the first national Medicare Part D contract for ZUNVEYL, which requires no prior authorization, thereby enhancing patient access ahead of schedule.
Alzheimer's disease affects approximately 7 million Americans, with over 11 million prescriptions written annually. However, more than half of patients discontinue treatment within a year due to side effects. ZUNVEYL's initial focus on the LTC market, which represents 36% of AD prescriptions and is valued at around $2 billion, positions it strategically within a critical segment of the healthcare industry. The achievement of Medicare coverage shortly after launch addresses a significant barrier to access for a large portion of the patient population, supporting Alpha Cognition's goal of capturing market share.
In the second quarter of 2025, ZUNVEYL generated $1.6 million in net product sales, contributing to a year-to-date net product revenue of approximately $2.0 million. Licensing revenue from the CMS partnership added $0.08 million. The high repeat-order rates and growing formulary wins underscore the potential for continued adoption momentum into the latter half of 2025. Alpha Cognition is also making progress in its intellectual property and pipeline, including the completion of a Department of Defense-funded pre-clinical study of ALPHA-1062 in a repetitive mild traumatic brain injury model, which showed promising results in reducing neuroinflammation and neuropathology.
Financially, Alpha Cognition reported total revenue of $1.66 million in the second quarter of 2025, a significant increase from none in the same period the previous year. The company ended the quarter with $39.4 million in cash and equivalents, providing approximately two years of runway at current burn rates. With a revised expectation for 2025 operating expenses of $34–38 million, down from prior guidance through cost optimization, Alpha Cognition is positioning itself for sustained growth in the Alzheimer's treatment market.
For more information on Alpha Cognition Inc. and its developments, visit https://www.alphacognition.com.
